The report covers emerging Vasomotor Symptoms drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Vasomotor Symptoms treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vasomotor Symptoms (Hot Flashes/Night Sweats): An Overview
Vasomotor Symptoms (VMS) are episodes of profuse heat accompanied by sweating and flushing, which are experienced majorly around the head, neck, chest, and upper back. Vasomotor symptoms are often accompanied by hot flashes and night sweats and are often considered as the cardinal symptoms of menopause. The VMS may also include heart palpitations and changes in blood pressure.
VMS is a form of temperature dysfunction that occurs due to changes in gonadal hormones. Normally, core body temperature (CBT) remains within a specific range, oscillating with daily circadian rhythms. Physiological processes that conserve and dissipate heat are responsible for maintaining CBT, and tight regulation is important for the maintenance of optimal internal organ function.
Menopause is a routine, non-pathologic condition involving the permanent cessation of menses for at least 12 months. Menopause occurs in all menstruating females due to non-pathologic estrogen deficiency. The median age of menopause is 51. Most women experience vasomotor symptoms, but menopause can affect many areas, some of which are the urogenital and cardiovascular systems.
Vasomotor Symptoms (Hot Flashes/Night Sweats) Market Key Facts
-
According to the North American Menopause Society, up to 75% of females in the United States experience hot flashes around menopause. Hot flashes usually occur over a period lasting from 6 months to 2 years, but a person can experience them for up to 10 years. In the US, menopause usually begins between the ages of 45 and 58 years. The average age for menopause is 52. A person enters menopause 12 months after their last period.
-
In 2022, the total prevalent cases of Vasomotor Symptoms were ~136,000,000 in the 7MM, which might decrease by 2032 at a mild CAGR. In the 7MM, the highest number of prevalent cases of Vasomotor Symptoms were observed in the US.
-
In EU4 and the UK, the prevalent cases of Vasomotor Symptoms were 59,500,000+ in 2022, which is estimated to decrease by the year 2032 at a mild CAGR. In the EU4 and the UK, the highest number of prevalent cases of Vasomotor Symptoms was observed in Germany.
-
According to the DelveInsight estimates, the total treated cases of Vasomotor Symptoms were 7,500,000+, in the 7MM, in the year 2022.
-
As per the DelveInsight estimates, the total prevalent cases of Vasomotor Symptoms were 21,600,000+ in 2022 in Japan.
Vasomotor Symptoms (Hot Flashes/Night Sweats) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Vasomotor Symptoms pipeline therapies. It also thoroughly assesses the Vasomotor Symptoms market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Vasomotor Symptoms drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Vasomotor Symptoms (Hot Flashes/Night Sweats) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Vasomotor Symptoms epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Vasomotor Symptoms epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Vasomotor Symptoms Epidemiology, Segmented as –
-
Total Prevalent Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
-
Total Treated Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
-
Total Severity-specific Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
-
Total Age-specific Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
Vasomotor Symptoms (Hot Flashes/Night Sweats) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Vasomotor Symptoms market or expected to be launched during the study period. The analysis covers the Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Vasomotor Symptoms drugs based on their sale and market share.
The report also covers the Vasomotor Symptoms pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Vasomotor Symptoms companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Vasomotor Symptoms Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/vasomotor-symptoms-market
Vasomotor Symptoms (Hot Flashes/Night Sweats) Therapeutics Analysis
The North American Menopause Society (NAMS) recommends no treatment until the hot flashes become bothersome to the woman. The decision to begin treatment should be based on the severity of symptoms, an assessment of treatment-related risks, and the woman’s attitudes about menopause and medications. In most women, hot flashes will abate over time without intervention. The treatment methods can include lifestyle modification, non-prescription remedies, hormonal options, and non-hormonal options.
The most commonly prescribed hormone is estrogen, used alone or with a progestogen for women with a uterus. Other hormones used include progestogens alone, oral contraceptives, androgen-estrogen, and custom hormonal preparations.
DUAVEE (bazedoxifene acetate/conjugated estrogens) is the first and only therapy to pair conjugated estrogens (CE) with an estrogen agonist/antagonist also known as a selective estrogen receptor modulator (SERM). DUAVEE uses bazedoxifene instead of a progestin to help protect the uterine lining against hyperplasia that may result from estrogen alone treatment. It was approved by the US FDA in October 2013, for the treatment of Vasomotor Symptoms Associated with Menopause.
In May 2023, the FDA approved VEOZAH (fezolinetant). It is the first drug specifically designed to reduce the frequency and severity of flushing and sweating spells that occur as a woman’s estrogen levels fall.
Vasomotor Symptoms (Hot Flashes/Night Sweats) Companies Actively Working in the Therapeutics Market Include
Some of the key companies in the Vasomotor Symptoms (Hot Flashes/Night Sweats) therapetuics market include TherapeuticsMD, Mithra Pharmaceuticals (Donesta Biosciences), KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas Pharma, Sojournix, Mitsubishi Tanabe Pharma, and others.
Emerging and Marketed Vasomotor Symptoms (Hot Flashes/Night Sweats) Therapies Covered in the Report Include:
-
DONESTA (E4, Estetrol): Mithra Pharmaceuticals
-
Elinzanetant (BAY-3427080): Bayer
-
Elismetrep (MT-8554): Mitsubishi Tanabe Pharma
-
Duavee/Duavive (bazedoxifene acetate/conjugated estrogens): Pfizer/Ligand Pharmaceuticals
-
VEOZAH (fezolinetant): Astellas Pharma
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/vasomotor-symptoms-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Vasomotor Symptoms Competitive Intelligence Analysis
4. Vasomotor Symptoms Market Overview at a Glance
5. Vasomotor Symptoms Disease Background and Overview
6. Vasomotor Symptoms Patient Journey
7. Vasomotor Symptoms Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Vasomotor Symptoms Treatment Algorithm, Current Treatment, and Medical Practices
9. Vasomotor Symptoms Unmet Needs
10. Key Endpoints of Vasomotor Symptoms Treatment
11. Vasomotor Symptoms Marketed Therapies
12. Vasomotor Symptoms Emerging Drugs and Latest Therapeutic Advances
13. Vasomotor Symptoms Seven Major Market Analysis
14. Attribute Analysis
15. Vasomotor Symptoms Market Outlook (In US, EU5, and Japan)
16. Vasomotor Symptoms Companies Active in the Market
17. Vasomotor Symptoms Access and Reimbursement Overview
18. KOL Views on the Vasomotor Symptoms Market
19. Vasomotor Symptoms Market Drivers
20. Vasomotor Symptoms Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/vasomotor-symptoms-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Glomerulonephritis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Glomerulonephritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Glomerulonephritis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research